Abstract
Allogenic hematopoietic stem cell transplant (alloSCT) is a potentially curative modality of treatment for patients with hematological malignancies. However, CNS complications following transplant pose a risk to survival of the patients. Early recognition and management of these complications are crucial to reduce morbidity and mortality of patients following transplant. Early CNS complications associated with alloSCT are infection, cerebrovascular events, chemotherapy and radiation-induced toxicities while late complications include post-transplant lymphoproliferative disorder, CNS relapse of underlying malignancy and viral and fungal infections. Development of graft-versus-host disease can further increase the risk of CNS complications and outcomes after alloSCT. Strategies aimed to reduce the risk of CNS complications and early management may ameliorate the morbidity and mortality in transplant recipients.
Original language | English (US) |
---|---|
Pages (from-to) | 2297-2312 |
Number of pages | 16 |
Journal | Future Oncology |
Volume | 13 |
Issue number | 25 |
DOIs | |
State | Published - Oct 2017 |
Keywords
- allogeneic hematopoietic stem cell transplant
- central nervous system complications
- survival
ASJC Scopus subject areas
- Oncology
- Cancer Research